SEC Form 4Coverage since Jun 1, 2026
$FDMT insider trading
Over the last 12 months, 4D Molecular Therapeutics insiders reported no purchases and 7 sales totaling $2.6M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $2.6M 7 events
- Events · 12m
- 7 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $FDMT · 12Mvia TradingView
Top insiders · 12m
Kirn DavidSee Remarks5× · $2.4M
Bizily ScottChief Legal Officer2× · $210K
All insider trades
7 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | Kirn DavidSee Remarks · O·D | ▼ Sale | 26,842 | $10.23 | $275K | -3.1% | plan |
| Aug 3, 2026 | Kirn DavidSee Remarks · O·D | ▼ Sale | 12,415 | $10.05 | $125K | -1.4% | plan |
| Jul 10, 2026 | Kirn DavidSee Remarks · O·D | ▼ Sale | 58,333 | $12.64 | $737K | -6.2% | plan · 3 tranches |
| Jun 30, 2026 | Bizily ScottChief Legal Officer · O | ▼ Sale | 6,566 | $14 | $92K | -43.2% | plan |
| Jun 23, 2026 | Bizily ScottChief Legal Officer · O | ▼ Sale | 9,810 | $12 | $118K | -53.2% | plan |
| Jun 22, 2026 | Kirn DavidSee Remarks · O·D | ▼ Sale | 114,746 | $10.47 | $1.2M | -10.9% | plan |
| Jun 1, 2026 | Kirn DavidSee Remarks · O·D | ▼ Sale | 1,922 | $10.02 | $19K | -0.2% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $FDMT feed.